August 7, 2022 11:27 am

A new social media platform Truthbook.social built by the people for the people, a force for good.

Pfizer to Test 3rd C0VID Shot in Kids Under 5 After Two Doses Fall Short

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

We are a not for profit Independent Media Group, which survives off donations. Even as little as $5 per month, from our generous readers. Please donate now, to help fund our work.

Pfizer to Test 3rd C0VID Shot in Kids Under 5 After Two Doses Fall Short

By Megan Redshaw

Pfizer and BioNTech will expand their clinical trial to include a third dose of their COVID vaccine on infants and children 6 months to 5 years old after the company said two doses failed to trigger a sufficient immune response in 2- to 5-year-olds.

Pfizer and BioNTech will test a third dose of their COVID vaccine on infants and children 6 months to 5 years old after the company said two doses failed to trigger a sufficient immune response in 2- to 5-year-olds.

The companies said on Dec. 17 they amended their clinical trial to include a third shot for the age group at least two months after the initial two-dose regimen.

The companies tested a 3 microgram dose of the vaccine — one-tenth of the adult dose — in children 6 months to 5 years of age. After two doses, children between 6 months and 2 years produced an immune response comparable to people aged 16 to 25 years, but children between 2 and 5 years old did not.

“The study will now include evaluating a third dose of 3 [micrograms] at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group,” the companies said in a press release.

In a Dec. 17 conference call with investors and analysts, Kathrin Jansen, Pfizer’s head of vaccine research, said if the revised strategy works, “we would have a consistent three-dose vaccine approach for all ages.”

If three doses trigger a sufficient immune response, the companies expect to submit the data to regulators in the first half of the year, The Washington Post reported.

“It is important to note that this adjustment is not anticipated to meaningfully change our expectations that we would file for Emergency Use Authorization and conditional approvals in the second quarter of 2022,” Jansen said.

“I think that a third dose will give a nice boost, and honestly, this is really exciting — as we know from the adult data, three doses is probably better for Omicron,” Dr. Kawsar Talaat, a principal investigator of the Pfizer pediatric trial and physician at Johns Hopkins Bloomberg School of Public Health, told The Washington Post. “And I think it’ll be good to have similar data for children.”

According to Pfizer’s press release, the phase 1/2/3 trial initially enrolled up to 4,500 children ages 6 months to under 12 in the U.S, Finland, Poland and Spain from more than 90 clinical trial sites.

Pfizer said its trial was designed to assess the safety, tolerability and immunogenicity of the Pfizer-BioNTech vaccine on a two-dose schedule in three age groups: ages 5 to under 12 years, ages 2 to under 5 years and ages 6 months to under 2 years.

The trial enrolled children with or without prior evidence of SARS-CoV-2 infection, despite more than 140 studies showing natural immunity derived from previous SARS-CoV-2 infection is long-lasting, robust and durable.

The companies also are testing a third dose in 5- to 11-year-olds and a third dose for adolescents between 12 and 17.

Pfizer-BioNTech said their decision was informed by comparing the immune response in the youngest children to older teens and young adults, and by emerging data — produced by Pfizer — that three doses are most protective against variants such as Omicron.The most recent data from the People’s Vaccine Alliance reveal Pfizer, BioNTech and Moderna are making combined profits of $65,000 every minute, or $93.5 million a day.

In its Q3 financial statement, Pfizer forecasts $36 billion in vaccine revenue for 2021, although gross profit from the revenue is split 50/50 with BioNTech.

During a February earnings call, Pfizer CEO Albert Bourla assured investors that as initial demand for its COVID vaccine subsides, the company could make significant profits by charging higher prices and implementing routine booster doses for new variants of the virus.

During the Barclays Global Health Conference in March, CFO Frank D’Amelio said the company doesn’t see vaccination as a one-time event, but “as something that’s going to continue for the foreseeable future.”

*Note We Deliberately Miss Spell Some Words or Add Capital Letters To Get Around Big Tech Censoring.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

Please support independent media and give a donation small priority large. This means we can continue to fight for friends and family to have a future and defend free speech.

Related News

Truthbook.social offering hundreds of thousands in giveaways for those joining its new social media platform as many desert Facebook in droves because of censoring

Here is some of the current incentives being offered to new users

Subscribe for free to our ANR news emails and access 2 free ebooks plus Reports to share with family and friends about Covid fraud and the danger of the vaccines.

For ANR Smaller Donors please donate below to help fund our critical not for profit work. Together we can defeat mainstream media.

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset.

and help us expose the Covid Fraudsters

Leave a Reply

Your email address will not be published.

Play Video

McIntyre Report
Political Talk Show

RT News - August 06 2022 (09:00 MSK)

We are not live at this moment. Please check back later.

Watch Now for Free

Share with friends now plus add us to your TV and other devices and help kill mainstream media

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on pinterest
Share on email

Click to Watch Now for Free

Jamie McIntyre
TruthBook.social Videos

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset.

and help us expose the Covid Fraudsters

Raw Report

Ryan Jackson Saw show

in USD

in AUD

in GBP

in CAD

Jamie McIntyre

ANR on

Currency Exchange Rates in AUD

Live and updated every minute of the day

Nurses Speak Out

Get our free News Emails on latest articles, alerts and solutions for both legal templates and ways to help fight back against the Globalists vax Mandates , and health resources to boost your immune system and ways to Protect from deadly EMF 5G radiation and more.

FREE E-BOOKS AND REPORTS ALSO

ANR Meme Report

with Nadine Roberts

Episode 002

21st Century Political System

Play Video

Editor's Pick

Thank you for visiting the
Australian National Review

To continue accessing more articles for free simply enter your email address

We are only 27% funded for next month's operations.

ANR is fully funded by our readers, people like you who often can’t stand mainstream media lies and propaganda. So please help us continue exposing the truth and helping defeat the Globalists and defend your and your children’s futures.

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset and help us expose the Covid Fraudsters

just $5 a month helps

Download the Full PDF - THE COVID-19 FRAUD & WAR ON HUMANITY